Ferroptosis
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S7243 | Ferrostatin-1 (Fer-1) | <1 mg/mL | 52 mg/mL | 52 mg/mL |
| S7699 | Liproxstatin-1 | <1 mg/mL | 68 mg/mL | 21 mg/mL |
| S7242 | Erastin | <1 mg/mL | 19 mg/mL | <1 mg/mL |
| S8254 | FIN56 | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S8155 | RSL3 | <1 mg/mL | 88 mg/mL | 22 mg/mL |
- Ferroptosis抑制剂（5）
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1)是一种有效的选择性的ferroptosis抑制剂，EC50为60 nM。 |
A, Indicated human PDAC cells were treated with erastin (2.5-40 μmol/L) with or without a cell death inhibitor (ferrostatin-1, 1 μmol/L; liprostatin-1, 1 μmol/L; ZVAD-FMK, 10 μmol/L; necrosulfonamide, 0.5 μmol/L) for 24 hours. Cell death was assayed using a CCK8 kit (n = 3;* , P < 0.05).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1是一种有效的ferroptosis抑制剂，IC50为22 nM。 |
(D) Indicated NRF2 knockdown HCC cells were treated with erastin (10 μM) and sorafenib (5 μM) with or without indicated inhibitors (ferrostatin-1, 1 μM; liproxstatin-1, 100 nM; ZVAD-FMK, 10 μM; necrostatin-1, 10 μM; necrosulfonamide, 0.5 μM) for 24 hours, and cell viability was assayed (n 5 3, *P < 0.05). Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. |
|
| S7242 |
ErastinErastin是一种ferroptosis激活剂，通过作用于线粒体VDAC而起作用，选择性作用于携带致癌基因RAS的肿瘤细胞。 |
Indicated HCC cells were treated with sorafenib (5 μM) and erastin (10 μM) with or without cell death inhibitors (ferrostatin-1, 1 μM; liprostatin-1, 100 nM; ZVAD-FMK, 10 μM; necrosulfonamide, 0.5 μM) for 24 hours, and cell viability was assayed (n=3, *P < 0.05 versus sorafenib or erastin treatment group).
|
|
| S8254 |
FIN56FIN56是ferroptosis的特异性诱导剂。 |
||
| S8155 |
RSL3RSL3是一种ferroptosis的激活剂，不依赖于VDAC，对携带致瘤性RAS的肿瘤细胞具有选择性。它结合并使GPX4失活，介导GPX4所调节的铁死亡。 |
Fluvastatin treatment of HT-1080 cells decreases GPX4 protein levels in a time- and concentration-dependent manner and synergized with co-treatment with the direct GPX4 inhibitor RSL3.
|
